Literature DB >> 24210808

²¹³Bi-anti-EGFR radioimmunoconjugates and X-ray irradiation trigger different cell death pathways in squamous cell carcinoma cells.

Anja Pickhard1, Guido Piontek, Christof Seidl, Samuel Kopping, Birgit Blechert, Martin Mißlbeck, Gero Brockhoff, Frank Bruchertseifer, Alfred Morgenstern, Markus Essler.   

Abstract

INTRODUCTION: Treatment of patients with squamous cell carcinoma of head and neck is hampered by resistance of tumor cells to irradiation. Additional therapies enhancing the effect of X-ray irradiation may be beneficial. Antibodies targeting EGFR have been shown to improve the efficacy of radiation therapy. Therefore, we analyzed cytotoxicity of (213)Bi-anti-EGFR immunoconjugates in combination with X-ray irradiation.
METHODS: The monoclonal anti-EGFR antibody matuzumab was coupled to CHX-A"-DTPA forming stable complexes with (213)Bi. Cytotoxicity of X-ray radiation, of treatment with (213)Bi-anti-EGFR monoclonal antibodies (MAb) or of a combined treatment regimen was assayed using cell proliferation and colony formation assays in UD-SCC5 cells. Key proteins of cell-cycle arrest and cell death were examined by Western blot analysis. Cell cycle analysis was performed by flow cytometry. DNA double-strand breaks were detected via γH2AX and quantified using Definiens™ software.
RESULTS: Irradiation with X-rays or treatment with (213)Bi-anti-EGFR-MAb resulted in median lethal dose (LD50) values of 12 Gy or 130 kBq/mL, respectively. Treatment with 37 kBq/mL of (213)Bi-anti-EGFR-MAb or 2 Gy of X-rays had only little effect on colony formation of UD-SCC5 cells. In contrast, a combined treatment regimen (37 kBq/mL plus 2 Gy) significantly decreased colony formation and enhanced the formation of DNA double-strand breaks. As revealed by flow cytometry, radiation treatments caused accumulation of cells in the G0/G1 phase. Both treatment with (213)Bi-anti-EGFR immunoconjugates and application of the combined treatment regimen triggered activation of genes of signaling pathways involved in cell-cycle arrest and induction of apoptosis like p21/Waf, GADD45, Puma and Bax, which were only marginally modulated by X-ray irradiation of cells.
CONCLUSIONS: (213)Bi-anti-EGFR-MAb enhances cytotoxicity of X-ray irradiation in UD-SCC5 cells most probably due to effective induction of DNA double-strand breaks. Induction of genes involved in cell-cycle arrest and cell death is almost exclusively due to (213)Bi-anti-EGFR-MAb and seems to be independent of p53 function.
© 2013.

Entities:  

Keywords:  Apoptosis; Cell-cycle arrest; Cytotoxicity; Head and neck squamous cell carcinoma; Radioimmunotherapy; UD-SCC5 cells; α-emitter (213)Bi

Mesh:

Substances:

Year:  2013        PMID: 24210808     DOI: 10.1016/j.nucmedbio.2013.09.010

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  4 in total

Review 1.  Improving external beam radiotherapy by combination with internal irradiation.

Authors:  A Dietrich; L Koi; K Zöphel; W Sihver; J Kotzerke; M Baumann; M Krause
Journal:  Br J Radiol       Date:  2015-03-18       Impact factor: 3.039

2.  Naive and radiolabeled antibodies to E6 and E7 HPV-16 oncoproteins show pronounced antitumor activity in experimental cervical cancer.

Authors:  R Phaëton; J Gutierrez; Z Jiang; R G Karabakhtsian; J Albanese; J Sunkara; D R Fisher; G L Goldberg; E Dadachova
Journal:  Immunotherapy       Date:  2015-06-22       Impact factor: 4.196

3.  Characterization of a novel single-chain bispecific antibody for retargeting of T cells to tumor cells via the TCR co-receptor CD8.

Authors:  Irene Michalk; Anja Feldmann; Stefanie Koristka; Claudia Arndt; Marc Cartellieri; Armin Ehninger; Gerhard Ehninger; Michael P Bachmann
Journal:  PLoS One       Date:  2014-04-21       Impact factor: 3.240

4.  Improved outcome of 131I-mIBG treatment through combination with external beam radiotherapy in the SK-N-SH mouse model of neuroblastoma.

Authors:  Aurélien Corroyer-Dulmont; Nadia Falzone; Veerle Kersemans; James Thompson; Danny P Allen; Sarah Able; Christiana Kartsonaki; Javian Malcolm; Paul Kinchesh; Mark A Hill; Boris Vojnovic; Sean C Smart; Mark N Gaze; Katherine A Vallis
Journal:  Radiother Oncol       Date:  2017-06-05       Impact factor: 6.901

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.